Loncar Cancer Immunotherapy ETF (CNCR): Price and Financial Metrics ETF
CNCR Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
Current price | $13.43 | 52-week high | $18.01 |
Prev. close | $13.29 | 52-week low | $11.68 |
Day low | $13.23 | Volume | 1,900 |
Day high | $13.50 | Avg. volume | 7,563 |
50-day MA | $12.77 | Dividend yield | N/A |
200-day MA | $14.13 |
CNCR Stock Price Chart Interactive Chart >
Loncar Cancer Immunotherapy ETF (CNCR) ETF Bio
The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.
CNCR ETF Info
Issuer | Exchange Traded Concepts |
Expense Ratio | 0.79% |
Underlying Index | Loncar Cancer Immunotherapy Index |
Asset Class | Equity |
Sector | Health & Biotech ETFs |
Assets Under Management (AUM) | 16.79M |
Net Asset Value (NAV) | $13.43 |
Options? | Yes |
Total Holdings | 32 |
CNCR Top Holdings
Symbol | Company | % of Total |
MRUS | MERUS NV | 0.06% |
CRSP | CRISPR THERAPEUTICS AG | 0.05% |
LEGN | LEGEND BIOTECH CORP-ADR | 0.05% |
IOVA | IOVANCE BIOTHERAPEUTICS INC | 0.04% |
RAPT | RAPT THERAPEUTICS INC | 0.04% |
BGNE | BEIGENE LTD-ADR | 0.04% |
ARGX | ARGENX SE - ADR | 0.04% |
MRK | MERCK & CO. INC. | 0.04% |
IMTX | IMMATICS NV | 0.04% |
CNCR Price Returns
1-mo | 2.05% |
3-mo | 0.00% |
6-mo | -10.82% |
1-year | -3.21% |
3-year | -45.63% |
5-year | -48.86% |
YTD | -2.18% |
2022 | -42.31% |
2021 | -19.24% |
2020 | 36.53% |
2019 | 24.22% |
2018 | -20.65% |